
    
      This study is designed to observe the incidence of monoclonal gammopathy of undetermined
      significance (MGUS) among obese patients planning to have weight reduction surgery or
      planning to enter into a physician monitored weight loss program and to follow the regression
      or progression of MGUS following surgery or the initiation of the weight loss program.
    
  